ESMO: European Society for Medical Oncology

1. A Spotlight on Precision Cancer Medicine

   Results fromtheTARGET, I-PREDICT and WINTHER studies released

2. FDA Approves Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma

   Approval is based on results from the KEYNOTE‑426 study

3. Innovation at the heart of breast cancer care: First ESMO Breast Cancer Congress [ESMO Media Alert]

   Innovative breast cancer treatment will be discussed during the first ESMO Breast Cancer Congress in Berlin

4. EMA Starts New Review of Risks with High-strength Estradiol-containing Creams

   Systemic absorption is of concern because it may result in side effects such as venous thromboembolism, stroke and endometrial cancer

5. FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma

   Approval of FGFR inhibitor is based on data from a cohort of patients enrolled on Study BLC2001